

QLQLQESGPGLVKPSSETLSLTCTVSGGSIR (SEQ ID NO: 76) or

QVQLQESGPGLVKPSSETLSLTCTVSGGSIR (SEQ ID NO: 77); (b) an FR-H2 comprising the amino acid sequence of WIRQPPGKGLEWIG (SEQ ID NO: 73); (c) an FR-H3 comprising the amino acid sequence of RVTISVDTSKNQFSLMLTSVTAADTAVYYCAR (SEQ ID NO: 74); and (d) an FR-H4 comprising the

amino acid sequence of WGQGTDTVTVSS (SEQ ID NO: 75) or WGNGTDTVTVSS (SEQ ID NO: 78). In some embodiments, the binding domain further comprises: (a) an HVR-L1 comprising the amino acid sequence of RASQSFSSSYLA (SEQ ID NO: 69); (b) an HVR-L2 comprising the amino acid sequence of GASSRAT (SEQ ID NO: 70); and (c) an HVR-L3 comprising the amino acid sequence of QQYDRSPLT (SEQ ID NO: 71). In some embodiments, the binding domain further comprises: (a) an FR-L1 comprising the amino acid sequence of EIVLTQSPGTLSPGERATLSC (SEQ ID NO: 79); (b) an FR-L2 comprising the amino acid sequence of WYQQKPGQAPRLLIY (SEQ ID NO: 80); (c) an FR-L3 comprising the amino acid sequence of GIPDRFSGSGSGTDFLTISRLEPEDFAVYYC (SEQ ID NO: 81); and (d) an FR-L4 comprising the amino acid sequence of FGGGTKVEIK (SEQ ID NO: 82).

In one aspect, the invention features an isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SFSX₁S (SEQ ID NO: 62), wherein X₁ is Met, Leu, or Val; (b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDX₁VKG (SEQ ID NO: 63), wherein X₁ is Ser or Ala; (c) an HVR-H3 comprising the amino acid sequence of ANYGX₁X₂FFEY (SEQ ID NO: 64), wherein X₁ is Asn or Asp, and X₂ is Trp or Phe; (d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4); (e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and (f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6). In some embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SFSMS (SEQ ID NO: 1); (b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDSVKG (SEQ ID NO: 2); (c) an HVR-H3 comprising the amino acid sequence of ANYGNWFFEY (SEQ ID NO: 3); (d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4); (e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and (f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6).

In another aspect, the invention features an isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36 and (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the VH domain further comprises: (a) an FR-H1 comprising the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 12); (b) an FR-H2 comprising the amino acid sequence of WVRQAPGKGLEWVA (SEQ ID NO: 13); (c) an FR-H3 comprising the amino acid sequence of RFTISRDDSKNTLYLQMNSLRAEDTAVYYCTR (SEQ ID NO: 14); and (d) an FR-H4 comprising the amino acid sequence of WGQGTDTVTVSS (SEQ ID NO: 15). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 36. In some

WHAT IS CLAIMED IS:

1. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs:
 - (a) an HVR-H1 comprising the amino acid sequence of SFSX₁S (SEQ ID NO: 62), wherein X₁ is Met, Leu, or Val;
 - (b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDX₁VKG (SEQ ID NO: 63), wherein X₁ is Ser or Ala;
 - (c) an HVR-H3 comprising the amino acid sequence of ANYGX₁X₂FFEY (SEQ ID NO: 64), wherein X₁ is Asn or Asp, and X₂ is Trp or Phe;
 - (d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4);
 - (e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and
 - (f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6).
2. The antibody of claim 1, wherein the binding domain comprises the following six HVRs:
 - (a) an HVR-H1 comprising the amino acid sequence of SFSMS (SEQ ID NO: 1);
 - (b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDSVKG (SEQ ID NO: 2);
 - (c) an HVR-H3 comprising the amino acid sequence of ANYGNWFFEY (SEQ ID NO: 3);
 - (d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4);
 - (e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and
 - (f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6).
3. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36 and (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 37.
4. The antibody of claim 3, wherein the VH domain further comprises:
 - (a) an FR-H1 comprising the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 12);
 - (b) an FR-H2 comprising the amino acid sequence of WVRQAPGKGLEWVA (SEQ ID NO: 13);
 - (c) an FR-H3 comprising the amino acid sequence of RFTISRDDSKNTLYLQMNSLRAEDTAVYYCTR (SEQ ID NO: 14); and
 - (d) an FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 15).
5. The antibody of claim 4, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 36.
6. The antibody of any one of claims 3-5, wherein the VL domain further comprises:
 - (a) an FR-L1 comprising the amino acid sequence of EIVLTQSPATLSLSPGERATLSC (SEQ ID NO: 25);

62. The composition of any one of claims 59-61, wherein the pharmaceutical composition further comprises an ST2 binding antagonist, a Factor D binding antagonist, an HtrA1 binding antagonist, a VEGF antagonist, a tryptase-beta binding antagonist, a chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) binding antagonist, an interleukin-13 (IL-13) binding antagonist, an interleukin-17 (IL-17) binding antagonist, a JAK1 antagonist, and/or an interleukin-5 (IL-5) binding antagonist.

63. The composition of claim 62, wherein the pharmaceutical composition comprises a Factor D binding antagonist.

64. The composition of claim 63, wherein the Factor D binding antagonist is an anti-Factor D antibody or an antigen-binding fragment thereof.

65. The composition of claim 62, wherein the pharmaceutical composition comprises an HtrA1 binding antagonist.

66. The composition of claim 65, wherein the HtrA1 binding antagonist is an anti-HtrA1 antibody or an antigen-binding fragment thereof.

67. The composition of claim 62, wherein the pharmaceutical composition comprises a VEGF antagonist.

68. The composition of claim 67, wherein the VEGF antagonist is an anti-VEGF antibody or an antigen-binding fragment thereof.

69. Use of the antibody of any one of claims 1-49 in the manufacture of a medicament for treating an IL-33-mediated disorder in a subject.

70. The use of claim 69, wherein the IL-33-mediated disorder is selected from the group consisting of an inflammatory condition, an immune disorder, a fibrotic disorder, an eosinophilic disorder, an infection, pain, a central nervous system disorder, a solid tumor, and an ophthalmologic disorder.

71. The use of claim 70, wherein the ophthalmologic disorder is selected from the group consisting of age-related macular degeneration (AMD), retinopathy of the eye, polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME), dry eye disease, Behcet's disease, retina detachment, glaucoma, uveitis, retinitis pigmentosa, Leber Congenital Amaurosis, Stargardt's disease, traumatic eye injury, and conjunctivitis.

72. The use of claim 71, wherein the AMD is wet AMD.

73. The use of claim 71, wherein the AMD is dry AMD.